Gossamer cuts loose 25% of its staff, ties future to phase 3 trial of tarnished Merck rival

Gossamer Bio is going all in on seralutinib, laying off 25% of its staff and stopping work on all other candidates to free up money for a phase 3 trial of its pulmonary arterial hypertension (PAH) prospect.